Biotechnology News and Research

RSS

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals, Inc. announced today the publication of the first human data from a case study of patients evaluated with its ophthalmic product candidate RGN-259. The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical Association peer-reviewed journal.

14 May 2010

Caliper Life Sciences' CDAS unit awarded new funding commitment for EPA ToxCast screening program

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $2.9 million under its contract with the Environmental Protection Agency for the EPA's ToxCast screening program.

14 May 2010

Phase 2a study results of Aerosurf for prevention of RDS in premature infants published

Discovery Laboratories, Inc., announces the publication of results from its previously-conducted Phase 2a feasibility study of Aerosurf, the Company's aerosolized KL4 surfactant, for the prevention of respiratory distress syndrome in premature infants, in the May 2010 issue of the Journal of Aerosol Medicine and Pulmonary Drug Delivery in the study titled "An Open Label, Pilot Study of Aerosurf Combined with nCPAP to Prevent RDS in Preterm Neonates".

14 May 2010

Redpoint Bio first-quarter 2010 net loss reduces to $1.7 million

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced its first quarter financial results for 2010.

14 May 2010

ISCA recommends chromosomal microarray as new standard for genetic evaluation of children

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with unexplained developmental delay, autism or birth defects.

14 May 2010

Emergent BioSolutions named Biotechnology Firm of the Year at TCM's Annual Tech Awards

Emergent BioSolutions Inc. announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland's Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland's biotechnology community as well as its presence and leadership within the state.

14 May 2010

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2010 and provided an update on its corporate developments.

14 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2010.

14 May 2010

caprotec bioanalytics closes EUR 4 million Series B Financing Round

caprotec bioanalytics GmbH today announced the closing of a EUR 4 million ($5.1M) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors. The proceeds will enable further development and marketing of the Company's proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures.

14 May 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

Fibrocell Science commences histology study of azficel-T for treatment of nasolabial fold wrinkles

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced the initiation of a small histology study (IT-H-001) of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles.

14 May 2010

Celsis IVT settles LiverPool patent infringement suit, XenoTech to stop sale of CryoXTreme products

Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.

14 May 2010

HIV disease tends to progress at faster rate in infected individuals who consume more alcoholic drinks

HIV disease tends to progress at a faster rate in infected individuals who consume two or more alcoholic drinks a day, according to an important new paper in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Omnicare announces $400M senior subordinated notes offering

Omnicare, Inc. today announced that it intends to offer $400 million aggregate principal amount of senior subordinated notes due 2020, pursuant to a preliminary prospectus supplement to be filed with the Securities and Exchange Commission under the Company's shelf registration statement.

13 May 2010

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Palatin Technologies, Inc., a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.

13 May 2010

Biotechnology News and Research

Data from RGN-259 study published in Archives of Ophthalmology

Caliper Life Sciences' CDAS unit awarded new funding commitment for EPA ToxCast screening program

Phase 2a study results of Aerosurf for prevention of RDS in premature infants published

Redpoint Bio first-quarter 2010 net loss reduces to $1.7 million

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

ISCA recommends chromosomal microarray as new standard for genetic evaluation of children

Emergent BioSolutions named Biotechnology Firm of the Year at TCM's Annual Tech Awards

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Neurologix reports lower net loss of $3.5M for first-quarter 2010

caprotec bioanalytics closes EUR 4 million Series B Financing Round

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

Fibrocell Science commences histology study of azficel-T for treatment of nasolabial fold wrinkles

Celsis IVT settles LiverPool patent infringement suit, XenoTech to stop sale of CryoXTreme products

HIV disease tends to progress at faster rate in infected individuals who consume more alcoholic drinks

Chimerix commences first-in-human study of CMX157 for HIV

Omnicare announces $400M senior subordinated notes offering

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News